Your browser doesn't support javascript.
loading
Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.
Lippi, Giuseppe; Adeli, Khosrow; Ferrari, Maurizio; Horvath, Andrea R; Koch, David; Sethi, Sunil; Wang, Cheng-Bin.
Afiliación
  • Lippi G; IFCC Taskforce on COVID-19, International Federation of Clinical Chemistry and Laboratory Medicine, Milan, Italy.
  • Adeli K; Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University Hospital of Verona, University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.
  • Ferrari M; IFCC Taskforce on COVID-19, International Federation of Clinical Chemistry and Laboratory Medicine, Milan, Italy.
  • Horvath AR; Clinical Biochemistry, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • Koch D; IFCC Taskforce on COVID-19, International Federation of Clinical Chemistry and Laboratory Medicine, Milan, Italy.
  • Sethi S; Vita-Salute San Raffaele University, Milan, Italy.
  • Wang CB; IFCC Taskforce on COVID-19, International Federation of Clinical Chemistry and Laboratory Medicine, Milan, Italy.
Clin Chem Lab Med ; 58(7): 1053-1062, 2020 06 25.
Article en En | MEDLINE | ID: mdl-32396137
ABSTRACT
Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Contención de Riesgos Biológicos / Pandemias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Clin Chem Lab Med Asunto de la revista: QUIMICA CLINICA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Contención de Riesgos Biológicos / Pandemias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Clin Chem Lab Med Asunto de la revista: QUIMICA CLINICA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2020 Tipo del documento: Article País de afiliación: Italia